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Here we introduce a new adenoviral vector where transgene expression is driven by p53. We first developed a synthetic promoter, referred to as
PGTxβ, containing a p53-responsive element, a minimal promoter and the first intron of the rabbit β-globin gene. Initial assays using plasmid-
based vectors indicated that expression was tightly controlled by p53 and was 5-fold stronger than the constitutive CMV immediate early
promoter/enhancer. The adenoviral vector, AdPG, was also shown to offer p53-responsive expression in prostate carcinoma cells LNCaP (wt p53),
DU-145 (temperature sensitive mutant of p53) and PC3 (p53-null, but engineered to express temperature-sensitive p53 mutants). AdPG served as
a sensor of p53 activity in LNCaP cells treated with chemotherapeutic agents. Since p53 can be induced by radiotherapy and chemotherapy, this
new vector could be further developed for use in combination with conventional therapies to bring about cooperation between the genetic and
pharmacologic treatment modalities.
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The development of new strategies for gene therapy may
involve improvement of vector engineering in order to better
gene transfer efficiency, specificity and expression level of the
therapeutic gene. Many different strategies have been described
for modulating transcription, such as the use of tissue-specific
promoters like prostate specific antigen (PSA) (Latham et al.,
2000; Wu et al., 2001), inducible promoters such as the tet-on,
tet-off system (Mizuguchi and Hayakawa, 2002), or promoters
which are sensitive to physiological alterations, including hif1α
and hif-responsive elements, activated in the hypoxic condition
(Ingram and Porter, 2005). Gene therapy for cancer may benefit
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doi:10.1016/j.virol.2007.11.015pharmacologic treatments may be combined. Matching che-
motherapeutics with the gene transfer strategy may achieve
synergistic effects, such as enhanced vector expression due to
drug activity, which in turn may provide increased transgene
activity, further sensitizing the cell to the drug and amplifying
the therapeutic benefit (Liu et al., 2005). Several pharmacologic
as well as genetic therapies rely on p53 activation in order to
control tumor growth and induce apoptosis. P53 is an important
tumor suppressor gene whose protein product acts as a strong
transcription factor (Ko and Prives, 1996; Resnick-Silverman
and Manfredi, 2006; Strano et al., 2007). P53 activity can be
induced by using chemotherapeutic drugs, such as doxorubicin
(dox), a topoisomerase II inhibitor which damages DNA (Kurz
et al., 2004). On the other hand, high doses of dox used for
cancer therapy may cause side effects due to non-specific
toxicity in cells other than the tumor (Bonadonna and
Monfardini, 1969). Moreover, p53 activity, in part, mediates
the apoptotic response to dox, suggesting that a lower dose of
drug could be used when the target cells express wild-type p53.
Currently, many gene therapy efforts are aimed at combining
9Rapid Communicationp53 gene transfer with chemotherapy with the hope of maxi-
mizing the effect of each of these treatment modalities (Nielsen
et al., 1998; Nishizaki et al., 2001; Quist et al., 2004). We have
shown previously the possibility of using p53 to drive transgene
expression from a retroviral vector where the long terminal
repeat (LTR) was modified by the insertion of a p53-responsive
element, resulting in an 8-fold improvement as compared to the
native retroviral LTR (Strauss et al., 2005; Strauss and Costanzi-
Strauss, 2004). In this report we describe a new adenoviral
vector, AdPG, which contains a synthetic, p53-responsive
promoter called PGTxβ. Upon insertion of the luciferase
reporter gene, expression from the AdPG-luc virus was
evaluated using a temperature sensitive (TS) mutant form of
p53, revealing an induction of up to 700-fold that was highly
specific and tightly regulated by p53. We also examined the
induction of endogenous p53 with dox as a mechanism to drive
vector expression in the target cell. In this manner, we present an
initial step towards the development of novel therapeutics based
on the combined gene therapy and chemotherapy approach.
Results
Construction and initial assays with p53-driven chimerical
promoters
The main purpose of this study was to engineer a new
adenoviral vector with the expression controlled by p53. The
first step was to develop a chimerical promoter which would
offer specificity and high-level expression when driven by p53.
The configuration of the chimerical promoter was derived
experimentally by comparing the ability of different versions to
drive luciferase expression in plasmid-based vectors. For these
initial assays, we developed the 293TS cell line which encodes a
temperature-sensitive p53 allele (p53TS), specifically, murine
p53 mutated at codon 135 (p53(135)) (Michalovitz et al., 1990).
p53(135) is transcriptionally inactive at 37 °C, but when shifted
to 32 °C, the conformation of the mutant protein changes and is
able to bind DNA and activate p53-responsive promoters. The
293TS cell line is easily transfected and permits the evaluation
of p53 activity on responsive promoters at the non-permissive
or permissive temperatures, revealing the levels of basal or
induced promoter activity.
As shown in Fig. 1, the pPG-luc vector, which contains the
p53-responsive element to drive luciferase expression, revealed
a high level of background at 37 °C and weak induction at 32 °C.
In the second construct, we inserted a minimal promoter
containing a TATA box sequence, derived from the adenovirus
E1B gene, downstream of the PG element, generating pPGTx-
luc. Although pPGTx-luc provided the tightest transcriptional
control depending on p53TS phenotype, it presented a relatively
low level of luciferase activity upon induction. The third version
of the chimerical promoter consisted of PGTx fused with a rabbit
β-globin intron, included to improve gene expression, generat-
ing pPGTxβ-luc. The pPGTxβ-luc vector presented the highest
level of luciferase activity in 293TS cells cultivated at 32 °C
when compared with pPG-luc and pPGTx-luc. With the pCMV-
luc control, as expected, there was no significant alteration inCMV promoter activity with respect to p53 phenotype or the
cultivation temperature. Interestingly, the luciferase activity
from the pPGTxβ-luc was comparable with that from pCMV-
luc. Therefore, the PGTxβ promoter arrangement was chosen
due its high expression potential and inducible characteristic.
The initial assays described above were performed in the
293TS cell line which contains endogenous p53 inactivated by
adenoviral E1B protein. The background level observed in the
absence of induction could be due to the endogenous p53 in the
293TS cells. In addition, the presence of E1B may have
interfered with the activity of p53(135). To address these
questions, we performed a co-transfection assay in the prostate
carcinoma cell line PC3, which lacks p53 expression, where
pPGTxβ-luc was introduced in the presence and in the absence
of an expression vector encoding wild-type p53. In this case, we
observed an extremely low level of luciferase activity in the
absence of p53, yet a nearly 50-fold level of induction in the
presence of p53(wt) (Fig. 2). As expected, luciferase activity
from pCMV-luc was not significantly altered by the presence of
p53(wt). Strikingly, the PGTxβ promoter arrangement was
approximately 5-fold stronger than the CMV promoter in PC3
cells. We conclude from these assays that the synthetic promoter
PGTxβ provided robust expression, even higher than the CMV
promoter, yet minimal background in the complete absence of
p53.
Functional assays of recombinant adenoviral vector AdPG-luc
in cell lines harboring p53TS
Based on the initial assays, the PGTxβ promoter arrange-
ment was chosen for further study. This chimerical promoter
was inserted in a recombinant adenovirus-5 vector, generating
AdPG. The luciferase cDNA was then inserted to serve as a
reporter in the AdPG-luc vector. The AdPG-luc virus was then
applied to prostate carcinoma cell lines harboring different
alleles of p53TS in order to investigate the p53-responsive
behavior of the new adenoviral vector when cultivated at 37 or
32 °C.
The first test of AdPG-luc was performed using DU-145, the
human prostate carcinoma cell line harboring an endogenous
p53TS allele (missense mutation at codon 223) (Bajgelman and
Strauss, 2006; Shiraishi et al., 2004). We transduced DU-145
with AdPG-luc adenovirus using a MOI of 50 and then cul-
tivated replicates at either 37 °C or 32 °C. As seen in Fig. 3A,
there was a 70-fold induction of luciferase activity at the
permissive temperature of 32 °C as compared with the non-
permissive temperature. A similar result was obtained in the
second test where we utilized PC3 cells stably expressing the
p53(223) allele (Fig. 3A), indicating that this allele was
responsible for the induction of the PGTxβ promoter at 32 °C
and also confirming the low background at 37 °C. Strikingly,
when PC3(143), PC3 cells with stable expression of the human
p53 temperature-sensitive mutant, p53(143) (Zhang et al.,
1994), were employed for this third assay of the AdPG-luc
vector, we observed a 700-fold induction of reporter gene
activity over the background level (Fig. 3B). Thus, the func-
tionality of the p53-driven adenoviral vector was confirmed.
Fig. 1. Development of the PGTxβ synthetic promoter. 293TS cells were seeded in 35-mm dishes and transfected with 4μg of (A) pPG-luc, (B) pPGTx-luc,
(C) pPGTxβ-luc or (D) pCMV-luc plasmid DNA. Cells were incubated at 37 °C (white bars) or 32 °C (black bars) and harvested after 16, 24 or 48 h, as indicated, and
luciferase assays were performed. Results are presented in arbitrary units (au) of luciferase activity (RLU/μg) without further normalization in order to reveal the
relative strength of each promoter arrangement. Results represent the average and standard deviation from 3 independent experiments.
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endogenous wild-type p53
These functional assays verified that AdPG-luc was tightly
regulated by p53, suggesting that AdPG-luc may prove to be a
useful reporter of p53 activity and serve as a sensor of the
cellular response to chemotherapeutic treatment. We chose the
human prostate carcinoma cell line LNCaP since it harbors
endogenous wild-type p53 and treatment with the DNA-
damaging agent doxorubicin (dox) due to its well-known
ability to induce p53. In Fig. 4A, we present a dose curve of
drug treatment, in which we observed an 8-fold induction of
luciferase activity using 200 ng/ml of dox. Interestingly, there
was no significant alteration in the cell cycle profile when using
dox concentrations at or below 200 ng/ml, but toxicity wasFig. 2. The promoter PGTxβ is tightly regulated by p53 and stronger than CMV
as assayed in PC3. Cells were seeded in 35-mm dishes and transfected with 4 μg
of pCMV-luc or pPGTxβ-luc and 2 μg of pCMVp53wt, as indicated. Luciferase
activity, presented in arbitrary units (au), was normalized using pPGTxβ-luc at
37 °C as 1. Results represent the average and standard deviation from 3
independent experiments.clearly observed above 200 ng/ml and may be related to the loss
of reporter activity. To determine whether chemotherapeutic
drug treatment may have a non-specific impact on expression
from the AdPG-luc virus, we treated the transduced cells withFig. 3. Robust expression from AdPG-luc can be driven by temperature-
sensitive alleles of p53. (A) DU-145 and PC3(223) cells were transduced with a
preparation of AdPG-luc, using a MOI of 50, and incubated at 37 °C or 32 °C, as
indicated. (B) PC3(223) and PC3(143) cells were transduced with a preparation
of AdPG-luc, using MOI of 50, and incubated at 37 °C or 32 °C, as indicated. In
each panel, luciferase activity, presented in arbitrary units (au), was normalized
considering the value obtained at 37 °C as 1. Results represent the average and
standard deviation from 3 independent experiments.
Fig. 4. Expression from AdPG-luc is regulated by endogenous p53 in LNCap.
Cells were seeded in 35-mm dishes, transduced with AdPG-luc usingMOI of 50,
and then incubated 24 h at 37 °C. After incubation, media were changed to
include the indicated amounts of drug. Cells were harvested 24h later for analysis
of both luciferase activity and cell cycle alteration. Luciferase activity, presented
in arbitrary units (au), was normalized considering the sample with transduction,
but without drug treatment, as 1. The first column in each panel represents non-
transduced cells as a negative control for luciferase activity. Results represent the
average and standard deviation from 3 independent experiments. (A) Dose curve
of the DNA-damaging and p53-inducing agent doxorubicin (dox). (B) Dose
curve of taxol, which acts independently of the p53 pathway.
11Rapid CommunicationTaxol, a non-genotoxic drug that is known not to induce p53. In
this case, we observed only slight variations in reporter activity,
yet the cell cycle was highly perturbed by drug treatment
(Fig. 4B). Taken together, these results suggest that the AdPG-
luc virus may be employed as an indicator of cellular response
to drug treatment.
Discussion
We have developed a new recombinant adenoviral vector
which contains a synthetic promoter, called PGTxβ, that is
composed of a p53-responsive element (PG) to act as an
enhancer (Kern et al., 1992), a minimal promoter (Tx) derived
from the adenoviral E1B gene and which improves transcrip-
tional control (Xavier-Neto et al., 1998) and an intronic
sequence (β), derived from the rabbit β-globin intron, included
to improve post-transcriptional regulation that results in
increased transgene expression (Schambach et al., 2000).
During the development of the PGTxβ promoter, we noted
that it could direct reporter gene activity to a level that surpassed
the widely used CMV immediate early promoter/enhancer. The
viral vector AdPG-luc was assayed in prostate carcinoma celllines that either lack p53 or contain wild-type or temperature-
sensitive mutant alleles of p53. We observed that AdPG-luc
expression was tightly regulated by p53 and that this vector may
prove useful as a sensor of cellular response to drug treatment.
As suggested by Wu et al. (2001), efforts to improve
transcriptional mechanisms in order to achieve adequate
transgene expression and increase the therapeutic benefit from
gene transfer vectors are of great importance (Wu et al., 2001).
Many approaches to gain appropriate transcriptional control in
viral vectors have been described. For example, therapeutic
strategies for prostate cancer using the tissue-specific PSA
promoter revealed some technical difficulties attributed to weak
expression (Latham et al., 2000; Yoshimura et al., 2001). In
comparison, use of the PGTxβ promoter yielded strong
expression and is specific for cells containing wild-type p53
activity. For applications in cells lacking p53 activity, the AdPG
vector may be modified by the insertion of the p53(wt) cDNA, a
strategy that we have previously shown to create a positive
feedback mechanism between the promoter and the transgene
(Strauss et al., 2005). We have also shown here that the PGTxβ
promoter, by way of p53, may be induced upon treating cells
with a therapeutically relevant drug.
We observed that different alleles of p53TS could exhibit
distinct transcriptional activities. In PC3(143) cells we observed
a 700-fold induction of luciferase activity over the background.
Interestingly, the temperature-sensitive behavior of p53(143)
has been previously described as dominant negative at 37 °C
and, upon shifting the cultivation temperature to 32 °C, its
transcriptional activity was stronger than that observed for
p53wt (Zhang et al., 1994). This is consistent with the strong
induction of AdPG-luc observed in PC3(143) cells. Another
consistent result was verified after comparing the magnitude of
transcriptional activity of p53(223) in the parental DU-143 cell
line and PC3(223). Both DU-145 and PC3(223) were transduced
with AdPG-luc, incubated at 37 °C and 32 °C, resulting in a 70-
and 60-fold induction of luciferase activity, respectively. These
results suggest that the expression from the AdPG-luc adeno-
virus, when driven by p53TS, was tightly regulated, yet achieved
a robust expression level upon p53 induction.
Assays performed with LNCaP, which encodes p53wt, have
shown the possibility of using AdPG-luc as a sensor of cellular
p53 activity in order to identify drugs that impact p53 function.
We imagine that the combination of drug-induced p53 activity
plus the introduction of a vector containing a p53-responsive
promoter could be developed into a new therapeutic approach
where the genetic and pharmacologic modalities act synergis-
tically. As shown here, activation of p53 with 200 ng/ml dox
resulted in an 8-fold induction of luciferase activity, yet no
significant cell cycle alteration was observed at this level of
drug. We propose that insertion of a therapeutically relevant
transgene in the place of luciferase may create the opportunity
for interplay between p53, the therapeutic transgene, the p53-
responsive promoter and the response to the chemotherapeutic
agent. In this scenario, a lower drug dose may still be sufficient
to activate viral expression and bring about a therapeutic benefit,
perhaps reducing the drug's impact on non-target (non-
transduced) cells.
12 Rapid CommunicationIn summary, we developed a new p53-driven adenoviral
vector which allows tight control over the transgene, yet
achieves a robust level of expression. Activation of endogenous
p53 was used to direct vector expression, modulating the ex-
pression level with chemotherapeutic treatment. These observa-
tions lead us to propose that, with further development, the
AdPG vector may be combined with lowered drug doses in
order to improve treatment, yet reduce side effects due to che-
motherapeutic toxicity.
Materials and methods
Construction of vectors
The PG element was isolated from PG13-CAT (Kern et al.,
1992). The fragment was inserted in PGL-3 (Promega-USA)
generating pPG-luc. Next, pPGTx-luc was constructed by
inserting the adenoviral E1B TATA-box (Xavier-Neto et al.,
1998) (referred to here as Tx) in pPG-luc. Finally, the rabbit
β-globin intron was isolated from phCMV-G (Burns et al., 1993)
and inserted upstream of the luc gene in pPGTx-luc in order to
generate pPGTxβ-luc. The adenoviral transfer vector pAdPG-
luc was constructed by inserting the cassette PGTxβ into the
vector pAd-luc-pA, which contains the luciferase cDNA plus
polyadenylation signal (pA) isolated from PGL-3 with BglII and
BamHI, and then cloned into the BglII site of pAdenovator
promoterless (Q-Biogene, USA). Following the manufacturer's
protocol, pAdPG-luc was recombined with the backbone vector
ΔE1/E3, of adenovirus serotype 5, generating the final AdPG-
luc construct (approximately 40 kb) which was verified by
restriction mapping. Cloning details provided upon request.
Cell lines
All lineages were cultivated in DMEM, supplemented with
10% bovine calf serum, in 5% CO2 at 37 °C or 32 °C, as
indicated. The 293TS cell line is a clone established from 293T
cells that were transfected with plasmid vector pBabep53(135)
puro (Michalovitz et al., 1990) and selected for puromycin
resistance. The cell line PC3(223) has been described previously
(Bajgelman and Strauss, 2006). The cell line PC3(143) was
established after G418 selection of PC3 cells previously trans-
duced with the retrovirus pCLp53(143) (Strauss et al., 2005).
Transfection assays
The cell line indicated in each experiment was seeded,
2.5×105 cells per 35-mm dish, and transfected the following
day with 4 μg of the indicated plasmid DNAs by the calcium–
phosphate precipitation method (Bajgelman et al., 2003). The
cells were then cultivated at 37 °C (or 32 °C where indicated)
for an additional 24 h before harvesting for assays.
Transduction assays
The cell line indicated in each experiment was seeded,
2.5×105 cells per 35-mm dish, and transduced the following dayusing a MOI of 50 of AdPG-Luc virus preparation diluted in
culture medium to a final volume of 700 μl. The transduction
was carried out at 37 °C for 24 h before removing the virus
preparation and adding fresh medium. The cells were then
cultivated at 37 °C (or 32 °C where indicated) for an additional
24 h before harvesting for assays or initiating drug treatments.
Taxol or doxorubicin treatments were carried out at the indicated
concentration during 24 h before harvesting for assays.
Virus preparations
Adenovirus (Ad) amplification and titration were performed
as described in the Adenovator kit (Q-Biogene, USA), but
purification was performed using the Adeno-X purification kit
(Clontech, USA) and then concentrated using Centricon
columns (Millipore, USA). Preparations were titered using
both spectrophotometry and cytopatic effect (CPE), yielding
titers of 8×1011 and 1×1011 particles/ml, respectively. The
MOI of 50 used in the assays was based the biologic titer.
Cell cycle assay
The trypsinized cells were fixed in 70% ethanol, washed
with phosphate-buffered saline (PBS) and then incubated with
propidium iodide (20 μg/ml) in RNase A (40 μg/ml) containing
PBS for 30 min at 37 °C. After washing, cells were analyzed by
flow cytometry (FACScan, Becton-Dickenson, USA).
Luciferase assay
Cells were harvested, washed with PBS and resuspended in
100 μl of 100 mM potassium phosphate (pH 7.8)/1 mM EDTA
then lysed by 3 cycles of freezing and thawing. Cell lysates were
then incubated with luciferase substrate reagent, LAR (Pro-
mega, USA) and the relative light units (RLU) from each
sample were determined with a Monolight 2010 luminometer.
The RLU for each sample was first normalized by protein
content using Bradford reagent (Bio-Rad, USA) and normalized
against the luciferase activity of the control condition indicated
in each figure legend, permitting the calculation of the average
and standard deviation between independent experiments.
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